tbuckley/cabot-search huggingface dataset:
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.
Authors: Anna Piskorz, Kevin K. Lin, James Anthony Morris, Elaina Mann, Amit M. Oza, Robert L. Coleman, David M. O'Malley, Michael Friedlander, Janiel M. Cragun, Ling Ma, Heidi Giordano, Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, James D. Brenton
Journal: Journal of Clinical Oncology (2016)

5549 Background: TP53 mutations are present in > 97% cases of high-grade serous ovarian cancer (HGSOC). Detection of TP53 mutations in ctDNA extracted from plasma has the potential to monitor disease course and treatment response. We have developed targeted amplicon deep sequencing (TADS) to detect low frequency mutations throughout the TP53 gene in ctDNA. Rucaparib is a potent PARP inhibitor in development for treatment of tumors with HR pathway deficiency. We used TADS to assess TP53 mutant allele fraction (MAF) in ctDNA from patients in ARIEL2, a phase II study of rucaparib for treatment of relapsed HGSOC (NCT01891344). Methods: Plasma samples (n = 65) were collected from 18 patients during screening, on day 1 of each cycle, and at the end of rucaparib treatment. DNA extracted from plasma underwent TADS of TP53 (median depth 6916×). FFPE tumor specimens were profiled using an NGS-based assay with a targeted gene panel including TP53. Response was assessed by RECISTv1.1 and GCIG CA-125 criteria. Results: Concordant TP53 mutations were detected in tumor and ctDNA from plasma of all 18 patients. Median TP53 MAF at screening and cycle 1 day 1 was 5.1% (IQR 1.1–17.5, n = 16) and 3.8% (IQR 0.68–10.3, n = 16), respectively. 14 patients were evaluable for response between cycle 1 and 2 (missing sample n = 2; TP53 MAF < 0.5% n = 2). 7/9 patients with > 50% reduction of TP53 MAF in ctDNA at cycle 2 achieved a RECIST PR (see Table); this included 5/6 patients with either a germline or somatic mutation in BRCA1/BRCA2. No patients with < 50% reduction at cycle 2 (n = 5) achieved RECIST response. Conclusions: Noninvasive detection of TP53 mutations by TADS is feasible, using plasma samples collected from women with relapsed platinum-sensitive HGSOC participating in an international multicenter trial. ctDNA is a promising biomarker for monitoring response to the PARP inhibitor rucaparib and will now be explored in all ARIEL2 subjects. Clinical trial information: NCT01891344.% TP53 MAF change C1-C2 Mutation status* RECIST Response −100 gBRCA1 PR −100 WT PR −96 gBRCA2 PR −88 sBRCA2 PR −80 gBRCA1 PR −74 WT PR −74 WT SD −66 WT SD −54 gBRCA1 PR −39 WT PD −18 WT SD −11 WT PD +86 WT PD +188 sBRCA1 SD *g, germline; s, somatic
A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors.
Authors: S. Alsamarai, L. Ravage-Mass, K. Kaley, G. Dutschman, W. Zhang, Z. Jiang, S. Liu, Y. C. Cheng, E. Chu, M. Saif
Journal: Journal of Clinical Oncology (2010)

e13571 Background: The goal of this phase I study was to determine the maximum tolerated dose (MTD) of the oral Chinese herbal medication PHY906 when combined with CPT-11. PHY906 has been used in Asia since 300 AD for symptoms including abdominal cramps, nausea/vomiting, and diarrhea. In this study, PHY906 was tested as a cytoprotective agent to reduce the GI toxicities of diarrhea and nausea/vomiting associated with CPT-11. Methods: Patients with metastatic/unresectable malignancies without standard treatment options were included and assigned to dose levels 1-5 with CPT-11 administered iv once every 2 weeks, beginning at a dose of 180 mg/m2 and escalating to 215 mg/m2 in dose level 4 and 250mg/m2 in dose level 5. PHY906 was administered orally twice daily on days 1-4 every 2 weeks from cycle 2 (cycle 1 in dose levels 4 and 5) starting at 1,200 mg twice per day and escalated to 1,800 mg twice daily in dose level 2 and 2,400 mg twice daily in dose levels 3 through 5. Extensive pharmacokinetic (PK) analyses were performed looking at the role of PHY906 on metabolism of CPT-11. Results: A total of 25 patients have been accrued to this study, and accrual is ongoing for dose level 4. Common treatment related grade 1 or 2 toxicities included anemia, fatigue, anorexia, nausea, and diarrhea. Grade 3 toxicities included leukopenia (n=2) and neutropenia (n=3). No grade 3 or higher diarrhea was noted in any dose level. In each of dose levels 1 and 2, one patient had grade 3 anorexia and nausea, and in dose level 3 one patient had grade 3 anorexia and vomiting. Grade 4 and 5 toxicities included leukopenia in dose level 2 (n=1) and febrile neutropenia in dose level 3 (n=1). PK analyses showed that PHY906 did not interfere with the metabolism or pharmacokinetics of CPT-11 as studied up to a total dose of 4.8 grams daily. No changes were observed in AUC levels of CPT-11 or its metabolites SN 38 and SN 38G. Conclusions: The combination of PHY906 with CPT-11 has been well tolerated with a manageable safety profile. Accrual is ongoing at higher CPT-11 doses to determine the optimal dose for the phase II study in patients with colon cancer. GI toxicities in the form of diarrhea and nausea/vomiting have been minimal. PK analysis reveals no interference of PHY906 on the metabolism of CPT- 11. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration PhytoCeutica PhytoCeutica Bayer, Bristol-Myers Squibb, Genentech, Novartis, Roche, sanofi-aventis Enzon, ImClone Systems, Merck, PhytoCeutica, Roche, Taiho Pharmaceutical
Mesures pour améliorer la surveillance bactériologique des endoscopes digestifs
Authors: B. Marchetti
Journal: Endoscopy (2016)

La surveillance bactériologique des endoscopes digestifs est un challenge permanent. Ce travail du Centre Hospitalier Universitaire de Brest est de grande qualité par rapport aux articles précédemment publiés au sujet des contrôles microbiologiques en endoscopie digestive.
Assessment of pexelizumab in acute myocardial infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Authors: Paul W Armstrong, Peter X Adams, Christian W Hamm, William W O'Neill, Alec S Vahanian, Christopher B Granger, David R Holmes, Thomas G Todaro, Frans Van de Werf
Journal: Circulation (2006)
Hepatic Encephalopathy is Associated with Persistent Learning Impairments despite Adequate Medical Treatment: A Multi-Center, International Study
Authors: S. Nardelli, S. Allampati, O. Riggio, K. Mullen, R. Prakash, S. Gioia, A. Unser, M. White, A. Fagan, J. Wade, A. Farcomeni, E. Gavis, J. Bajaj
Journal: Journal of Hepatology (2016)
Inhibition of the CA2+-Inhibited Adenylyl Cyclase 5 Reduces CYST Growth in Mice with Polycystic Liver Disease (ADPKD) Caused by Defective Polycystin-2
Authors: C. Spirli, V. Mariotti, A. Villani, L. Fabris, R. Fiorotto, M. Strazzabosco
Journal: Journal of Hepatology (2016)
Immune Exhaustion and 2B4 Expression in Human T-Cell Lymphotropic Virus Type 1(HTLV-1) Infection
Authors: Ezinne Chioma Chibueze, Yohann White, Makoto Yoshimitsu, Tomohiro Kozako, Shinsuke Suzuki, Kakushi Matsushita, Kimiharu Uozumi, Naomichi Arima
Journal: Blood (2012)
Small amounts of alcohol increase risk of atrial fibrillation, study finds
Authors: Anne Gulland
Journal: BMJ (2016)

Regularly drinking even small amounts of alcohol could lead to an enlarged atrium, increasing the risk of atrial fibrillation, a study in the Journal of the American Heart Association has found.1

Although alcohol consumption has been associated with atrial fibrillation in several large epidemiological studies, the exact mechanism behind the link is unknown.

Researchers examined the link between cumulative alcohol consumption and the risk of atrial fibrillation in 5220 Framingham Heart Study participants, whose median age was 56.3 years and 54% of whom were women. Researchers …
Lean-Non-Alcoholic Fatty Liver Disease with Central Visceral Obesity Identifies Patients with More Severe Disease
Authors: R. Lombardi, L. Mensi, G. Pisano, P. Dongiovanni, C. Bertelli, E. Fatta, L. Valenti, S. Fargion, A.L. Fracanzani
Journal: Journal of Hepatology (2016)
Yes, rolling averages are a good way to assess training load for injury prevention. Is there a better way? Probably, but we have not seen the evidence
Authors: M K Drew, P Blanch, C Purdam, T J Gabbett
Journal: British Journal of Sports Medicine (2016)

The acute:chronic workload ratio (ACWR) is evidence based1 ,2 and is strongly supported by the available literature.3 Other models of injury risk have yet to show such support.

We find …
Exercise cardiac MRI-derived right ventriculo-arterial coupling ratio detects early right ventricular maladaptation in PAH
Authors: Aaron C.W. Lin, Wendy E. Strugnell, Helen Seale, Benjamin Schmitt, Michaela Schmidt, Rachael O'Rourke, Richard E. Slaughter, Fiona Kermeen, Christian Hamilton-Craig, Norman R. Morris
Journal: European Respiratory Journal (2016)

Exercise intolerance and right ventricular (RV) dysfunction are cardinal features of pulmonary arterial hypertension (PAH). Despite the significantly elevated afterload, patients rarely experience symptoms at rest until the late stages of the disease. Recent data suggest that the ability of the right ventricle to adapt to increased afterload is an important determinant of exercise capacity and outcome in PAH [1]. RV ejection fraction (RVEF) has been demonstrated to predict outcome [2]. There is also growing evidence that a noninvasively derived right ventriculo-arterial coupling ratio (VACR) may provide important prognostic information [3]. However, it remains unclear to what extent RV contractility is impaired during exercise and which metric best describes ventricular functional adaptation to afterload in PAH. We aimed to evaluate and compare the effects of submaximal exercise on RV systolic function and VACR in PAH and healthy subjects using cardiac magnetic resonance (MRI). We also examined and compared VACR and cardiopulmonary exercise test (CPET) in estimating the severity of disease. In well-compensated PAH, early RV maladaptation is best captured by changes in SV/ESV at exercise by cardiac MRI <http://ow.ly/MyEi302UUeL>
Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69 − CD56 dim cells
Authors: Nicole Marquardt, Eliisa Kekäläinen, Puran Chen, Egle Kvedaraite, Jennifer N. Wilson, Martin A. Ivarsson, Jenny Mjösberg, Lena Berglin, Jesper Säfholm, Martijn L. Manson, Mikael Adner, Mamdoh Al-Ameri, Per Bergman, Ann-Charlotte Orre, Mattias Svensson, Barbro Dahlén, Sven-Erik Dahlén, Hans-Gustaf Ljunggren, Jakob Michaëlsson
Journal: Journal of Allergy and Clinical Immunology (2016)
P0996 : The effects of short-term exenatide on circulating adiponectin levels in patients with type 2 diabetes mellitus (DMT2) with or without non-alcoholic fatty liver disease (NAFLD): a randomized, open-label, controlled intervention trial
Authors: S. Savvidou, K. Karatzidou, A. Gagalis, K. Tsakiri, P. Hytiroglou, J. Goulis
Journal: Journal of Hepatology (2015)
High Risk for Hepatocellular Carcinoma in Cirrhotic Patients with SVR following IFN-Free Daa Treatment within 1 Year Follow-Up
Authors: K. Kozbial, R. Stern, C. Freissmuth, S. Beinhardt, A.F. Stättermayer, P. Munda, M. Trauner, P. Ferenci, H. Hofer, Viral Hepatitis
Journal: Journal of Hepatology (2016)
Degree of Concordance between Peripheral Blood Leukemic Blast Count and Mid Induction Bone Marrow in Childhood Acute Lymphoblastic Leukemia.
Authors: Mahasen M. Al-Saleh, Tarek Owaidah, Saad Al-Daama, Hind A. Al-Humaidan, Emad Mousa, Tarek Al-Asaad, Ameurfina Silo, Asim Belgaumi
Journal: Blood (2004)
Entecavir versus Lamivudine for Prevention of Liver-Related Events in Patients with HBV-Related Advanced Liver Disease: A Multicenter, Prospective Study
Authors: J.Y. Park, S.G. Kim, W.Y. Tak, H.J. Yim, B.K. Jang, M.Y. Kim, B.I. Kim, J.-W. Lee, K.T. Yoon, J.Y. Cheong, S.Y. Kwon, T.Y. Kim, S.H. Bae, Y.S. Seo, J.H. Kwon, D.J. Kim, J.-K. Kim, S.W. Jeong, S.H. Ahn, K.-H. Han
Journal: Journal of Hepatology (2016)
Cross-Species Investigations Reveal Role, Mechanism and Predictive Power of Paracrine, Secondary Senescence in B-Cell Lymphoma Therapy
Authors: Jan R. Dörr, Maja Milanovic, Yong Yu, Julia Kase, Dido Lenze, Michael Hummel, Gunnar Dittmar, Bernd Dörken, Georg Lenz, Soyoung Lee, Clemens A Schmitt
Journal: Blood (2012)
Low Molecular Weight Heparin Treatment Does not Increase the Risk of Bleeding after Prophylactic Endoscopic Variceal Band Ligation in Patients with Cirrhosis
Authors: M. Bianchini, G. Cavani, A. Bonaccorso, L. Turco, A. Merighi, E. Villa, F. Schepis
Journal: Journal of Hepatology (2016)
Preferential Accumulation of Graft Infiltrating T Helper Cells but Not Cytotoxic T Cells Distinguishes Subclinical Rejection from Acute Cellular Rejection in Human Liver Allografts
Authors: R. Taubert, A. Baumann, F. Noyan, M. Hardtke-Wolenski, J. Schlue, F. Lehner, M. Manns, E. Jaeckel
Journal: Journal of Hepatology (2016)
In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral Activity and Improved Resistance Profile in HCV Patients with Genotypes 1, 2, and 3 Infections
Authors: E. Asante-Appiah, W. Marshall, E. Gane, S. Popa, P. McMonagle, S. Curry, L. Maganti, W. Gao, G. Garrett, C. Cilissen, I. De Lepeleire, T. Black, D. Hazuda, J. Butterton
Journal: Journal of Hepatology (2016)
In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX- 1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia Cells.
Authors: Irene Homminga, Christian M Zwaan, Chantal Y. Manz, Shanta Bantia, Cynthia Parker, Jessica Buijs-Gladdines, Wilco Smits, Martin A. Horstmann, Rob Pieters, Jules P.P. Meijerink
Journal: Blood (2008)
Inosine Triphosphatase Deficiency does not Predict Anaemia during Ribavirin Containing DAA All Oral Regimens for HCV
Authors: S. De Nicola, E. Galmozzi, A. Aghemo, R. D’Ambrosio, E. Degasperi, M. Borghi, M. Colombo
Journal: Journal of Hepatology (2016)
Identification of a Discrete Subpopulation of T-Cells Over-Expressing HDAC11 with a TH17 Phenotype
Authors: Karrune Woan, Fengdong Cheng, Hongwei Wang, Jennifer Rock-Klotz, Zi Wang, Yu Yu, Edward Seto, Noreen Luetteke, Xue-Zhong Yu, Alejandro Villagra, Eduardo M. Sotomayor
Journal: Blood (2010)
Relationship between Alcohol use Disorders and Response to Antiviral Treatment on the Prognosis of Cirrhotic Patients with Chronic Hepatitis C
Authors: P. Sultanik, L. Kramer, S. Bouam, A. Vallet-Pichard, H. Fontaine, M. Corouge, V. Thepot, B. Lavielle, P. Sogni, S. Pol, V. Mallet
Journal: Journal of Hepatology (2016)
No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the Trio Network
Authors: N. Afdhal, B. Bacon, M. Curry, D. Dieterich, S. Flamm, L. Guest, K. Kowdley, Y. Lee, N. Tsai, Z. Younossi
Journal: Journal of Hepatology (2016)
A Reversible Cause of Left Ventricular Dysfunction
Authors: Thomas Nguyen, Amina Khaldi, Ruben Casado-Arroyo
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia.
Authors: Tait D. Shanafelt, Nancy D. Bone, Susan M. Geyer, Betsy LaPlant, Thomas E. Witzig, Susan Schwager, Gordon W. Dewald, Greg S. Nowakowski, Renee C. Tschumper, Clive S. Zent, Timothy G. Call, Diane F. Jelinek, Neil E. Kay
Journal: Blood (2006)
Population-Based Clinical Cohort Allows Mapping of Hepatocellular Carcinoma Incidence and Risk Factors to Enable Targeted Surveillance
Authors: T.P. Hong, P. Gow, M. Fink, A. Dev, S. Roberts, A. Nicoll, J. Lubel, I. Kronborg, N. Arachchi, M. Ryan, W. Kemp, V. Knight, H. Farrugia, V. Thursfield, P. Desmond, A.J. Thompson, S. Bell
Journal: Journal of Hepatology (2016)
Safety of Simeprevir-Based Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Observational Study
Authors: M. Colombo, M. Russello, P. Forte, G. Lettieri, L. Milazzo, A. Gasbarrini, A. Ori, M. Palma, R. Termini, G.B. Gaeta
Journal: Journal of Hepatology (2016)
Clinical Effect of Sex-Specific Cutoff Values of High-Sensitivity Cardiac Troponin T in Suspected Myocardial Infarction
Authors: Maria Rubini Giménez, Raphael Twerenbold, Jasper Boeddinghaus, Thomas Nestelberger, Christian Puelacher, Petra Hillinger, Karin Wildi, Cedric Jaeger, Karin Grimm, Karl-Frieder Heitzelmann, Zaid Sabti, Patrick Badertscher, Janosch Cupa, Ursina Honegger, Nicolas Schaerli, Nikola Kozhuharov, Jeanne du Fay de Lavallaz, Beatriz Lopez, Emilio Salgado, Òscar Miró, F.Javier Martín-Sánchez, Esther Rodríguez Adrada, Beata Morawiec, Jiri Parenica, Eva Ganovska, Claire Neugebauer, Katharina Rentsch, Jens Lohrmann, Stefan Osswald, Tobias Reichlin, Christian Mueller
Journal: JAMA Cardiology (2016)

It is currently unknown whether the uniform (universal clinical practice for more than 2 decades) or 2 sex-specific cutoff levels are preferable when using high-sensitivity cardiac troponin T (hs-cTnT) levels in the diagnosis of acute myocardial infarction (AMI).To improve the management of suspected AMI in women by exploring sex-specific vs uniform cutoff levels for hs-cTnT.In an ongoing prospective, diagnostic, multicenter study conducted at 9 emergency departments, the present study evaluated patients enrolled from April 21, 2006, through June 5, 2013. The participants included 2734 adults presenting with suspected AMI. Duration of follow-up was 2 years, and data analysis occurred from June 5 to December 21, 2015.The final diagnosis was centrally adjudicated by 2 independent cardiologists using all available information, including measurements of serial hs-cTnT blood concentrations twice: once using the uniform 99th percentile cutoff value level of 14 ng/L and once using sex-specific 99th percentile levels of hs-cTnT (women, 9 ng/L; men, 15.5 ng/L).Diagnostic reclassification in women and men using sex-specific vs the uniform cutoff level in the diagnosis of AMI.Of the 2734 participants, 876 women (32%) and 1858 men (68%) were included. Median (interquartile range) age was 68 (55-77) and 59 (48-71) years, respectively. With the use of the uniform cutoff value, 127 women (14.5%) and 345 men (18.6%) received a final diagnosis of AMI. Among these, at emergency department presentation, levels of hs-cTnT were already above the uniform cutoff value in 427 patients (sensitivity, 91.3% [95% CI, 85%-95.6%] in women vs 90.7% [95% CI, 87.1%-93.5% in men]; specificity, 79.2% [95% CI, 76.1%-82.1%] in women vs 78.5% [95% CI, 76.4%-80.6%] in men). After readjudication using sex-specific 99th percentile levels, diagnostic reclassification regarding AMI occurred in only 3 patients: 0.11% (95% CI, 0.02-0.32) of all patients and 0.6% (95% CI, 0.13-1.85) of patients with AMI. The diagnosis in 2 women was upgraded from unstable angina to AMI, and the diagnosis in 1 man was downgraded from AMI to unstable angina. These diagnostic results were confirmed when using 2 alternative pairs of uniform and sex-specific cutoff values.The uniform 99th percentile should remain the standard of care when using hs-cTnT levels for the diagnosis of AMI.
Pathophysiological role of hormones and cytokines in cancer cachexia.
Authors: H. Park, H. Kim, J. Kwon, J. Yun, S. Lee, S. Bae, C. Kim, N. Lee, D. Hong
Journal: Journal of Clinical Oncology (2010)

9053 Background: Cancer-induced cachexia is the most common paraneoplastic syndrome and is recognized as an indicator of poor prognosis. Cancer cachexia differs from starvation, but has not been fully elucidated. We investigated the role of fasting hormones (adiponectin, ghrelin, and leptin) and pro-inflammatory cytokines (TNF-α, IFN-γ, and IL-6) in cancer patients. Methods: Hormones (ghrelin, adiponectin, and leptin) and cytokines (TNF-α, IFN-γ, and IL-6) were measured by ELISA or RIA in lung cancer and colorectal cancer patients before the administration of cancer therapy, and measurements were repeated every 2 months for a total of three times. Results: From June 2006 to August 2008, 42 patients were enrolled. In total, 21 patients were included in the cachexia group and the others served as a comparison group. Similar distributions in terms of age, diagnosis, and levels of hemoglobin (Hb), CRP, glucose, and insulin were observed in both groups, but the cachectic patients included more males than females, and these patients had lower albumin levels. No significant difference in the initial adiponectin, ghrelin, TNF-α, IFN-γ, or IL-6 level was observed between groups, although leptin was significantly lower in cachectic patients than in the comparison group (15.3 ± 19.5 vs. 80.9 ± 99.0 pg/ml, P = 0.007). Hormone and cytokine levels did not differ between colorectal and lung cancer patients. During the follow-up, the patients who showed a > 5% weight gain had higher ghrelin levels (weight gain vs. no change vs. weight loss: 1223.1 ± 383.7 vs. 594.2 ± 218.1 vs. 654.3 ± 218.1 pg/ml, P = 0.007) after 6 months and lower cytokine levels (TNF-α, IFN-γ, and IL-6) than the control, but the differences were not statistically significant. Patients exhibiting elevated IL-6 levels typically showed a weight loss > 5% after 6 months. Conclusions: A blunted adiponectin or ghrelin response to weight loss may contribute to cancer cachexia. Patients with initially higher levels of IL-6 experienced weight loss. After 6 months, those who had gained weight (> 5%) showed elevated ghrelin levels, and therefore a clinical trial examining the effect of ghrelin treatment on cancer cachexia may be warranted. No significant financial relationships to disclose.
Hematopoietic Stem/progenitor Cells Contribute to Atherosclerotic Progression Via Integrin aM beta(2)
Authors: Mingming Gao, Sarah Schouteden, Anton Roebroek, Kristel Eggermont, Paul Holvoet, Paul P Van Veldhoven, George Liu, Catherine Verfaillie, Yingmei Feng
Journal: Circulation (2013)
Legalise medicinal cannabis, MPs urge
Authors: Anne Gulland
Journal: BMJ (2016)

A cross party group of MPs and peers has urged the government to legalise cannabis for medicinal purposes.

In a new report the All Party Parliamentary Group on Drug Policy Reform has called for the reclassification of cannabis to enable patients to get hold of the drug “without suffering the added stress of breaking the law.”1

Cannabis is currently listed under schedule one, the schedule for dangerous drugs with no medicinal value. However, the government has approved the cannabis derivative nabiximols (Sativex) for the treatment of spasticity and the synthetic cannabinoid nabilone to control nausea …
Biochemical and In Vivo Characterization of Amino Acid Substitutions in the Runx1 (AML1) Runt Domain Found in FPD/AML, AML M0, and Cleidocranial Dysplasia (CCD) Patients.
Authors: Christina J. Matheny, Takeshi Corpora, Maren E. Speck, Ting-Lei Gu, John H. Bushweller, Nancy A. Speck
Journal: Blood (2004)